FDA granted Priority Review to Belite Bio's tinlarebant NDA for Stargardt Disease Type 1, setting a PDUFA date of Feb. 12, 2027. The filing is supported by Phase 3 DRAGON trial data showing a 35.7 percent reduction in atrophic retinal lesion growth versus placebo. If approved, tinlarebant would be the first FDA-approved treatment for the estimated 53,000 Americans with STGD1.
FDA granted Priority Review to Belite Bio's tinlarebant NDA for Stargardt Disease Type 1, with a Feb. 12, 2027 PDUFA date.
"The acceptance of our NDA with Priority Review designation shows the immediate need among the Stargardt disease community for an approved treatment option," Dr. Tom Lin, Chairman and CEO of Belite Bio, said.
The filing is based on the Phase 3 DRAGON trial, which showed a statistically significant 35.7 percent reduction in the growth rate of atrophic retinal lesions compared with placebo, measured as definitely decreased autofluorescence by fundus autofluorescence imaging. Tinlarebant was generally well tolerated, with side effects consistent with its mechanism of action. If approved, tinlarebant would be the first FDA-approved treatment for STGD1, a rare inherited retinal disease caused by mutations in the ABCA4 gene that affects an estimated 53,000 people in the U.S.
Tinlarebant is a once-daily oral small molecule that reduces serum retinol binding protein 4 (RBP4), the sole carrier protein transporting retinol from the liver to the eye. By limiting retinol delivery to the retina, the drug reduces the formation of bisretinoids — vitamin A-based toxins that drive retinal degeneration in Stargardt Disease and contribute to geographic atrophy in advanced dry age-related macular degeneration.
The drug holds Breakthrough Therapy, Fast Track, and Rare Pediatric Disease designations from the FDA, plus Orphan Drug status in the U.S., Europe, Japan, and Switzerland, and Sakigake designation in Japan. Belite Bio is also evaluating tinlarebant in the Phase 2/3 DRAGON II trial in STGD1 patients and the Phase 3 PHOENIX trial in geographic atrophy.
STGD1 is the most common inherited macular dystrophy, typically manifesting in the first or second decade of life and resulting in irreversible central vision loss. Management has been limited to low-vision rehabilitation and visual aids, with no pharmacologic therapy approved to date.
"As a practicing physician, I have treated people living with Stargardt disease for more than 20 years and have seen firsthand the challenges that it brings," Dr. Hendrik Scholl, Chief Medical Officer of Belite Bio, said. "As of now, the only options that we have to offer people as their blindness progresses are visual aids."
The Priority Review designation shortens the FDA's standard 10-month review to six months, reflecting the agency's assessment that tinlarebant, if approved, would offer a significant improvement over available therapy in a condition with no approved treatments. Belite Bio shares trade on Nasdaq under the ticker BLTE, with a market capitalization of approximately $6.5 billion and a consensus analyst rating of Buy with a $200 price target. The company's next milestone is the FDA's PDUFA decision on Feb. 12, 2027, which will determine whether tinlarebant becomes the first approved pharmacologic option for the estimated 53,000 Americans living with STGD1.
This article is for informational purposes only and does not constitute investment advice.
